Why Healthcare Still Can’t Measure What Really Drives Disease — and How GlycanAge Is Changing That

Across Europe and increasingly in the United States, healthcare systems are under growing pressure to move upstream. Aging populations, rising chronic disease burden, and escalating costs are forcing a mindset shift from treatment to prevention. Yet while policymakers, insurers, and providers recognize prevention as a strategic priority, changing an entire system is challenging, and clinical practice still lacks the tools to measure it meaningfully and consistently.

Among the companies working to address this gap, GlycanAge has emerged as one of the most advanced platforms translating glycobiology into clinical application, built on decades of research and focused on turning the biology of aging into measurable, actionable clinical insights. 

By analyzing IgG glycosylation patterns, GlycanAge enables the tracking of chronic inflammation and immune system aging over time, offering a longitudinal view of health that has traditionally been missing from standard diagnostics.

What began as a scientific exploration of how sugar molecules regulate immune function has evolved into a platform now used in more than 1,600 clinics across over 60 countries, with more than 30,000 tests performed globally. This expansion reflects a broader shift in how health is being understood: not as a series of isolated clinical events, but as a continuous biological process that can be measured, monitored, and potentially influenced.

The relevance of this shift is becoming increasingly visible across both clinical and economic dimensions. Chronic diseases account for nearly 74% of global deaths, according to the World Health Organization. At the same time, European populations continue to age rapidly. Eurostat projects that by 2050, almost 30% of the EU population will be aged 65 or older.

Healthcare systems are already absorbing the consequences. The OECD highlights that chronic diseases represent the largest share of healthcare expenditure across developed economies, driven primarily by long-term management rather than acute intervention. In parallel, the global preventive healthcare market, estimated at $243 billion in 2023, is projected to more than double by 2030, as stated by Grand View Research — a shift that GlycanAge is helping translate into measurable clinical practice.

Demand is already moving. Infrastructure is still catching up.

A System Designed for Disease, Not for Its Timeline

European healthcare systems, whether publicly funded or insurance-based, are among the most advanced in the world. Yet they share a structural characteristic: they are optimized to respond once disease becomes clinically visible.

In Germany, chronic diseases account for the majority of healthcare expenditure, with long-term treatment pathways placing sustained pressure on both public and private payers. In the United Kingdom, the NHS has repeatedly emphasized prevention as essential to long-term sustainability, yet continues to operate within a model largely driven by diagnosis and intervention.

This dynamic is not unique to Europe. In the United States, where healthcare spending exceeds 17% of GDP, a significant portion of costs is still associated with managing chronic conditions that could be addressed earlier. Across systems, the pattern is consistent: intervention begins when symptoms appear, not when biological processes start to shift.

The limitation is not strategic intent, but the absence of continuous biological visibility, something GlycanAge’s work in measuring long-term immune system behavior begins to make possible in clinical practice.

The Missing Layer: Measuring the Process, Not the Outcome

Most clinical measurements capture endpoints.

Blood pressure, lipid levels, glucose markers, and imaging results are essential tools, but they provide snapshots of risk at specific moments in time. They do not describe how that risk develops.

Chronic diseases are not events. They are trajectories. Up to 80% of premature heart disease and stroke cases could be prevented through earlier intervention and risk management, as reported by the World Health Organization.

Over the past two decades, research has increasingly converged on one of the underlying mechanisms shaping these trajectories: chronic, low-grade inflammation. The concept of inflammaging describes how the immune system gradually shifts toward a pro-inflammatory state, influencing a wide range of age-related conditions.

Despite its relevance, this process remains difficult to measure in clinical practice. Traditional inflammatory markers are highly sensitive to short-term fluctuations and do not capture underlying patterns over time, a limitation GlycanAge addresses through glycan-based analysis of immune system function.

This creates a structural disconnect. Healthcare systems aim to prevent diseases driven by long-term biological changes, yet rely on tools that primarily detect short-term variation. This gap is not only clinical, but consequential at scale. Approaches like those developed by GlycanAge begin to close this gap by enabling the measurement of these long-term biological processes, making earlier visibility, and therefore earlier intervention, increasingly possible.

From Episodic Diagnostics to Longitudinal Biology

A different approach is beginning to emerge, based on measuring biological processes over time rather than at isolated points.

Glycan analysis represents one of these approaches. Changes in IgG glycosylation patterns reflect how the immune system behaves across longer periods, providing insight into cumulative inflammatory states rather than temporary responses.

GlycanAge has focused on translating this research into a standardized test that can be repeated, enabling clinicians to observe how a patient’s biological age evolves and how it responds to interventions. Instead of a single data point, the result becomes a trajectory. This has allowed GlycanAge not only to generate biological insights, but to make them repeatable and usable in real clinical environments, which is where many preventive approaches tend to break down.

A similar shift has already taken place in industries where early signals determine outcomes. In aviation, for example, predictive maintenance has replaced reactive repair models by continuously monitoring system performance and identifying deviations before failure occurs. Airlines now rely on real-time diagnostics to reduce downtime, prevent accidents, and optimize operational costs.

Healthcare is approaching a comparable transition, where understanding how a system changes over time becomes more valuable than observing its state at a single moment.

What Changes When Biology Becomes Trackable

When biological processes can be measured consistently over time, several consequences follow.

Intervention can begin earlier, before structural damage occurs. This is particularly relevant for cardiovascular and metabolic diseases, where risk accumulates gradually. The European Society of Cardiology emphasizes that atherosclerosis, for example, develops silently over decades before clinical symptoms appear, meaning that earlier detection of underlying processes can significantly improve long-term outcomes.

Treatment can become more adaptive. Instead of relying solely on population-level guidelines, clinicians can adjust interventions based on how an individual’s biology responds, improving both effectiveness and efficiency.

Health systems can begin to align incentives with outcomes. Prevention becomes measurable, which makes it possible to evaluate and reward improvements in long-term health rather than volume of care.

For companies like GlycanAge, this creates a pathway beyond diagnostics. The ability to monitor biological aging longitudinally positions such platforms within a broader ecosystem that includes clinical decision-making, preventive strategies, and population health management.

A Market Shaped by Structural Pressure

The scale of this opportunity is not defined by a single geography.

In high-income markets such as Western Europe and the United States, the pressure to reduce the long-term cost of chronic disease is intensifying. In the US alone, chronic diseases account for approximately 90% of the $4.5 trillion annual healthcare expenditure.

At the same time, system inefficiencies remain significant. Reports from organizations such as the Commonwealth Fund consistently rank the US healthcare system among the highest in spending but lowest in outcomes compared to peer nations, highlighting a structural imbalance between cost and effectiveness. In this context, the economic argument for earlier, more precise intervention is no longer theoretical. It is becoming operational.

In emerging markets, the dynamics are different but no less relevant. Access to healthcare remains uneven, and prevention is often constrained by both infrastructure and affordability. Expanding access to measurable health insights, particularly through scalable and standardized approaches, can complement existing systems, extending their capabilities rather than replacing them, enabling earlier awareness and intervention where traditional pathways may be limited.

This is not about replacing healthcare systems, but about extending their reach. An approach that GlycanAge is making operational through measurable, longitudinal health insights.

From Research to Clinical Practice

The transition from discovery to adoption remains complex. Healthcare systems require evidence, standardization, and integration into existing workflows. Clinicians need to understand how to interpret new types of data and how to incorporate them into decision-making processes.

This is why the current phase of the field is defined less by theoretical validation and more by practical application.

• How should inflammaging be measured in a clinical setting?
• What constitutes a meaningful change over time?
• How can these measurements inform treatment decisions?

These questions are increasingly shaping both clinical research and market development. GlycanAge sits within this transition, not as a standalone solution, but as part of a broader effort to bring measurable, longitudinal biology into everyday clinical decision-making.

On June 20, GlycanAge will host the “Inflammaging in Clinical Practice” satellite event in Dubrovnik, held alongside the ISABS Conference and in collaboration with Mayo Clinic. The focus reflects the shift underway: not whether inflammaging matters, but how it can be integrated into everyday medical practice.

Healthcare is moving, gradually but decisively, from treating disease to managing biological trajectories.

The ability to measure those trajectories, consistently and at scale, is becoming essential not only for improving outcomes, but for enabling healthcare systems to function sustainably in the decades ahead.